This article is more than 5 years old. Information may no longer be current.
Concomitant boost thoracic radiation plus chemotherapy benefited NSCLC patients
Click Here to Manage Email Alerts
A combination of concomitant boost thoracic radiation plus systemic chemotherapy appeared safe and effective among patients with locally advanced non–small cell lung cancer, according to phase 2 study results.
Researchers evaluated accelerated hyperfractionation with concomitant boost thoracic radiation for 20 working days in doses of 64 Gy to the gross tumor volume, and 40 Gy to the elective clinical target volume. Patients also received cisplatin on day 1 and vinorelbine on days 1 and 8, with a 3-week interval.
All 55 patients in the population completed the concomitant boost thoracic radiation, and 94.5% received at least two cycles of the chemotherapy combination.
The overall response rate was 93.6%, with 69.1% of patients achieving a partial response and 24.5% achieving a complete response.
Median PFS was 16.7 months, and median OS was 58.2 months.
The most common adverse events were grade 3 esophagitis (18.2%) and grade 3 radiation pneumonitis (3.6%).
“The results from concurrent chemoradiation therapy are still disappointing, although long-term survival can be observed in certain populations of the patients,” the researchers wrote. “Concurrent chemoradiation therapy using concomitant boost thoracic radiation with concurrent [cisplatin and vinorelbine] is safe and effective for locally advanced NSCLC, with good PFS and excellent OS.”
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts